Da An Gene secures new chikungunya virus detection kit approval

Guangzhou Da An Gene Co., Ltd. (Da An Gene) has announced the acquisition of a new medical device registration certificate from the National Medical Products Administration. The certificate is for a "Chikungunya Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" and is valid until September 24, 2030.

The kit is intended for the in vitro qualitative detection of Chikungunya virus nucleic acid in serum samples from suspected cases and others requiring diagnosis. The company emphasizes that detection results are for clinical reference only and should not be the sole basis for diagnosis, recommending integration with patient symptoms and other laboratory tests.

This new registration enriches Da An Gene's product offerings and broadens its application areas. The company noted that the product is currently in the market development phase, and market demand remains uncertain, advising investors to be aware of potential investment risks.